We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M Turnover 69.23%
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+8.45%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$17.4M
AUM Growth
-$93.9M
Cap. Flow
-$95.1M
Cap. Flow %
-545.17%
Top 10 Hldgs %
70.1%
Holding
52
New
9
Increased
–
Reduced
16
Closed
27
Avg Time Held
0.5 years
Top 10 Avg Time Held
0.1 years
Top 20 Avg Time Held
0.2 years

Top Buys

Rank Stock Value
1
AXNX icon
Axonics, Inc. Common Stock
AXNX
+$1.39M
2
ICLR icon
Icon
ICLR
+$947K
3
LH icon
Labcorp
LH
+$837K
4
EHC icon
Encompass Health
EHC
+$834K
5
PFE icon
Pfizer
PFE
+$477K

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$15.5M
2
BRKR icon
Bruker
BRKR
+$6.93M
3
AZN icon
AstraZeneca
AZN
+$6.53M
4
ELV icon
Elevance Health
ELV
+$5.03M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.87M

Sector Composition

Rank Sector Weight
1 Healthcare 98.36%
2 Real Estate 1.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BSX icon
1
Boston Scientific
BSX
$65.3B
$2.26M 12.96%
39,108
-8,785
-18% -$469K
2023 Q2
2 quarters
TMO icon
2
Thermo Fisher Scientific
TMO
$251B
$2.01M 11.55%
3,794
-10,055
-73% -$4.87M
2023 Q3
1 quarter
AXNX icon
3
DELISTED
Axonics, Inc. Common Stock
AXNX
$1.55M 8.87%
+24,871
New +$1.39M
2023 Q4
0 quarters
ELV icon
4
Elevance Health
ELV
$93.3B
$1.24M 7.1%
2,627
-10,874
-81% -$5.03M
2022 Q3
5 quarters
ICLR icon
5
Icon
ICLR
$13B
$1.04M 5.94%
+3,659
New +$947K
2023 Q4
0 quarters
LH icon
6
Labcorp
LH
$25.9B
$906K 5.19%
+3,984
New +$837K
2023 Q4
0 quarters
EHC icon
7
Encompass Health
EHC
$12B
$859K 4.92%
+12,870
New +$834K
2023 Q4
0 quarters
PODD icon
8
Insulet
PODD
$9.8B
$848K 4.86%
3,906
-4,972
-56% -$853K
2023 Q3
1 quarter
HOLX icon
9
DELISTED
Hologic
HOLX
$831K 4.76%
11,631
-6,119
-34% -$426K
2023 Q3
1 quarter
ZBH icon
10
Zimmer Biomet
ZBH
$18.1B
$687K 3.94%
5,646
-11,833
-68% -$1.32M
2023 Q3
1 quarter
AVTR icon
11
Avantor
AVTR
$11B
$562K 3.22%
24,598
-202,279
-89% -$4.14M
2023 Q3
1 quarter
THC icon
12
Tenet Healthcare
THC
$21.4B
$552K 3.16%
7,303
-19,848
-73% -$1.26M
2021 Q2
10 quarters
PFE icon
13
Pfizer
PFE
$168B
$455K 2.61%
+15,790
New +$477K
2023 Q4
0 quarters
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$10.6B
$448K 2.57%
4,650
-174,918
-97% -$15.5M
2022 Q2
6 quarters
KIDS icon
15
OrthoPediatrics
KIDS
$575M
$437K 2.5%
13,428
-56,936
-81% -$1.65M
2023 Q2
2 quarters
CI icon
16
Cigna
CI
$78.9B
$414K 2.38%
1,384
-4,699
-77% -$1.37M
2021 Q2
10 quarters
QDEL icon
17
QuidelOrtho
QDEL
$875M
$379K 2.17%
5,147
-21,600
-81% -$1.46M
2023 Q3
1 quarter
COO icon
18
Cooper Companies
COO
$11.1B
$374K 2.14%
3,952
-42,180
-91% -$3.54M
2023 Q3
1 quarter
SBRA icon
19
Sabra Healthcare REIT
SBRA
$4.87B
$286K 1.64%
20,017
-183,775
-90% -$2.61M
2023 Q3
1 quarter
A icon
20
Agilent Technologies
A
$47.9B
$264K 1.51%
+1,900
New +$226K
2023 Q4
0 quarters
FTRE icon
21
Fortrea Holdings
FTRE
$2.13B
$244K 1.4%
+6,988
New +$214K
2023 Q4
0 quarters
QGEN icon
22
Qiagen
QGEN
$9.6B
$227K 1.3%
+4,922
New +$209K
2023 Q4
0 quarters
HUM icon
23
Humana
HUM
$49.8B
$215K 1.23%
469
-6,115
-93% -$3.01M
2023 Q3
1 quarter
COR icon
24
Cencora
COR
$64.9B
$203K 1.17%
990
-10,616
-91% -$2.07M
2023 Q3
1 quarter
ACRS icon
25
Aclaris Therapeutics
ACRS
$512M
$156K 0.89%
+148,400
New +$453K
2023 Q4
0 quarters
1
2 3

Similar funds

UVM
Upfront Ventures Management Santa Monica, California $12.3M AUM
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.5M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Endurant Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Endurant Capital Management held 52 positions worth $17.4M, down 84% from $111M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Endurant Capital Management withdrew a net $95.1M in Q4 2023, closing 27 positions and reducing 16 holdings. Its most notable exit was Bruker, an estimated $6.93M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 95% a quarter earlier, followed by Real Estate.

Against the trend, Endurant Capital Management opened a new position in Axonics, Inc. Common Stock worth $1.55M.

  • Endurant Capital Management's largest Q4 2023 buy was Axonics, Inc. Common Stock: 24,871 shares worth $1.55M.
  • Endurant Capital Management's biggest Q4 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $15.5M.
  • Endurant Capital Management fully exited Bruker in Q4 2023, selling an estimated $6.93M.
  • Endurant Capital Management's ten largest holdings make up 70% of its $17.4M portfolio in Q4 2023.
  • Endurant Capital Management opened 9 new positions and closed 27 in Q4 2023.
  • Endurant Capital Management's portfolio value fell 84% quarter-over-quarter to $17.4M.

Based on Endurant Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.